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Summary : Remifentanil has important side effects and
it is not easy to know what remifentanil concentrations
should be used during different endpoints of anaesthesia.
We analyzed the remifentanil predicted effect-site con-
centrations (RemiCe) at different events during neuro-
surgical procedures and assessed if the concentrations
used were clinically adequate. BIS and haemodynamic
parameters were collected every 5 seconds. Predicted
cerebral concentration of propofol (PropCe) and RemiCe
were analyzed immediately prior to respective stimulus,
and 30, 60 and 90 seconds after. RemiCe were 2.2 ± 0.3,
6 ± 2.6 and 2.2 ± 0.9 ng ml-1 at intubation, incision and
extubation, respectively. PropCe observed in the same
periods were 5 ± 1, 2.6 ± 0.9 and 1 ± 0.3 µg ml-1, also
respectively. The remifentanil concentrations used in our
patients were lower than reported concentrations, while
being clinically adequate to minimize the haemodynam-
ic response to stimulation.
Key words : Remifentanil ; intubation ; incision ;
extubation.
INTRODUCTION
Total intravenous anaesthesia (TIVA) is wide-
ly used. Some advantages of this technique have
contributed to its acceptance by anaesthesiologists :
it allows each component of anaesthesia to be regu-
lated independently and adapted to noxious stimu-
lation during surgery, it is very easy to use, provides
good haemodynamic stability and a smooth recov-
ery from anaesthesia (4, 7). Target-controlled
infusion (TCI) with propofol and remifentanil is a
common anaesthetic choice for neurosurgical
procedures (6). TCI with these two drugs based
on published pharmacokinetic/pharmacodynamic
models (11, 13, 17) is being widely studied (2, 14,
15). Although remifentanil allows easy titration of
analgesic levels and easy adaptation to different lev-
els of stimulation, when combined with propofol it
may cause hypotension and bradicardia (10).
TCI is a recent technique for the administra-
tion of intravenous agents based on real-time phar-
macokinetic simulations. Its aim is to control and
maintain adequate levels of drugs and effects.
However, the therapeutic window is narrow with IV
agents. Concentrations below the minimal threshold
have the risk of awareness, recall and/or movement.
By the contrary, an overconcentration leads to
hypotension and ventilatory depression (20). When
anaesthesiologists begin to use TCI systems some
difficulties are usually encountered, namely in
selecting the appropriate target concentrations for
remifentanil at specific key points, such as intuba-
tion, incision and extubation. Nevertheless, anaes-
thesiologists have been prone to use TCI due to its
great potential (5, 14, 16).
In this study, we assessed if remifentanil con-
centrations based on our previous clinical experi-
ence were sufficient to prevent haemodynamic
responses to stimulation at different events during
neurosurgical procedures in patients under general
anaesthesia with TCI with propofol and remifen-
tanil.
METHODS
Patients and equipment
Data were collected during twenty-five neuro-
surgical interventions (Research Committee
(Acta Anaesth. Belg., 2006, 57, 265-270)
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approval and informed consent), under general
anaesthesia with target controlled infusion using
propofol (Fresenius) and remifentanil (GSK,
Ultiva). Two anaesthesiologists blinded to the
objective of the study were involved. Patients with
severe cardiac pathologies, uncontrolled hyperten-
sion or under medications influencing the central
nervous system were not included in the study.
Electroencephalographic data was collected
using an A-2000XP BIS monitor (Aspect Medical
Systems) with BIS-Sensors® (Aspect medical
Systems) placed on the forehead of each patient
according to the manufacturer instructions.
Haemodynamic data was collected using an AS3
Datex monitor (Datex –Engstrom). Propofol and
remifentanil were administered using two Asena
Alaris syringe pumps. Both monitors and the
syringe pumps were connected by a RS-232 inter-
face to a personal computer running RugLoop II®
software (developed by Tom De Smet (Demed
Engineering, Temse, Belgium) and Michel Struys
(Ghent University, Gent, Belgium)). RugLoop II®
with the Minto and colleagues (12, 13) and
Schnider and colleagues (17) pharmacokinetic/
pharmacodynamic models for remifentanil and
propofol, respectively, was used to control the
syringe pumps. Blood pressure measurements dur-
ing induction of anaesthesia and intubation were
performed non-invasively using the AS3 continuous
measurements mode (“STAT” mode). Patients sub-
jected to craniotomies had arterial invasive meas-
urements following intubation. Patients subjected to
non-craniotomies procedures had non-invasive
blood pressure monitoring every minute after
induction of anaesthesia.
Anaesthetic protocol
Propofol and remifentanil were administered
using a peripheral venous cannula inserted in the
forearm of each patient. A saline solution was
administered at a constant infusion rate of 400 ml h-1
to assure the homogeneous administration of the
anaesthetic drugs. All other required drugs and flu-
ids were administered in a separate venous line.
Patients were pre-medicated with 10 mg of
diazepam per os, two hours before entering the sur-
gery room. Induction of anaesthesia was performed
by a continuous infusion rate of 200 ml hr-1 of
propofol until loss of consciousness. At this
moment, propofol infusion was changed to TCI
with a propofol effect-site target equal to that
observed at loss of consciousness ; based on our
previous experience in the operating theatre with
neurosurgical patients, a remifentanil infusion was
also initiated at a plasmatic concentration target of
2.5 ng ml-1 until intubation. A 1 mg kg-1 rocuronium
IV was administered before tracheal intubation.
After intubation, propofol concentrations were
titrated to a BIS target level of hypnosis of 40 to 60
and remifentanil concentrations were adjusted to a
minimum, maintaining heart rate and mean arterial
pressure values stabilized according to the individ-
ual patient’s needs. Before skin incision, the anaes-
thesiologists increased the remifentanil target con-
centration to a level that they felt adequate for each
individual patient, provided that the remifentanil
effect site concentrations were above 3 ng ml-1. The
skin was not infiltrated with any anaesthetic solu-
tion. During the maintenance phase of anesthesia
(time between incision and the stop of propofol
infusion), propofol was adjusted to a BIS target
level of hypnosis of 40 to 60 ; remifentanil was
adjusted to surgical stimuli. After skin closure,
propofol infusion was stopped. Extubation was per-
formed after the patients were awake and breathing
spontaneously. Remifentanil infusion was main-
tained during extubation and continued for one
hour, with decreasing rate in the recovery room.
Paracetamol (1 gr) and parecoxib (40 mg) were
given about one hour before the end of surgery. No
opioids other then remifentanil were given before
extubation.
Data analysis
Data of propofol and remifentanil predicted
cerebral concentrations, BIS, heart rate and systolic
blood pressure were analyzed immediately prior to
the respective stimulus (intubation, incision and
extubation) and at 30, 60 and 90 seconds after the
respective using repeated measurements analysis of
variance. The software of MATLAB 6.5.1 (The
MathWorks®, Natick, MA) was used for statistical
analysis ; P < 0.05 was considered significant. Data
are quoted as mean ± sd.
RESULTS
Twenty two ASA I-III patients, age 46 ±
12 years (age range 20-74), weight 67 ± 13 kg,
height 163 ± 8 cm, thirteen females were studied.
Eleven patients were submitted to craniotomies pro-
cedures with invasive blood pressure measurements
(starting after intubation) ; eleven patients were sub-
mitted to non-craniotomies procedures (8 spinal,
1 cranioplasty and 2 ventricular-peritoneal shunts)
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with non invasive blood pressure measurements
throughout the entire procedures. Three patients
were excluded due to failures in the protocol.
Rocuronium 1 mg kg-1 was administered 3.1 ±
0.8 minutes before intubation.
Table I shows the remifentanil and propofol
predicted cerebral concentrations, systolic blood
pressure, heart rate and BIS at intubation, incision
and extubation and at each 30 seconds after. At
intubation, systolic blood pressure and heart rate
increased significantly (P < 0.01) ; remifentanil
and propofol predicted effect site concentrations at
intubation were 2.2 ± 0.3 ng ml-1 and 5 ± 1 µg ml-1,
respectively. All other variables did not show any
significant change during all time periods studied.
Individual haemodynamic and BIS changes
observed at intubation, incision and extubation are
shown in figure 1.
DISCUSSION
We observed a maximum increase of 9% in
systolic blood pressure 60 seconds after orotracheal
intubation and a 12% maximum increase in heart
rate 30 seconds after orotracheal intubation.
Although the remifentanil plasma target of
2.5 ng ml-1 had been achieved in all patients before
intubation, in some patients the effect site concen-
tration was slightly below 2.5 ng ml-1 at the time of
intubation. GUIGNARD and colleagues (8) reported
that remifentanil prevented increases in haemody-
namic variables associated with laryngoscopy and
tracheal intubation in a dose-dependent fashion :
effect site concentrations of 4 ng ml-1 attenuated or
even abolished the haemodynamic responses to
intubation. In our study, the remifentanil predicted
effect site concentrations at intubation were 2.2 ±
0.3 ng ml-1 which can be considered adequate if we
look at the haemodynamic responses. The increase
in systolic blood pressure (9%) and heart rate (12%)
observed in our study following intubation,
although statistically significant, occurred during a
brief period of time and may be considered clinical-
ly acceptable. The use of higher doses of remifen-
tanil would probably result in marked hypo-
tension (10) pre-laryngoscopy, without clinically
relevant attenuation of the haemodynamic respons-
es to orotracheal intubation.
The intensity of noxious stimuli varies in a
very significant way throughout a given procedure,
requiring frequent dose adjustments. It is difficult to
completely abolish the haemodynamic responses
without taking unnecessary risks, such as severe
hypotension and bradicardia. At skin incision, when
the noxious stimulus is intense, the target concen-
tration of the opioid must be increased. At any tar-
get change it must be taken into account the period
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Table I
Predicted propofol (PropCe) and remifentanil (RemiCe) cerebral concentrations at intubation, incision and
extubation. Systolic blood pressure values (SBP ; mmHg), heart rate (HR ; bpm) and BIS at the time imme-
diately prior (T0) to intubation, incision and extubation, and 30 (T30), 60 (T60) and 90 (T90) seconds after.
After intubation, systolic blood pressure (ANOVA P = 0.003) and heart rate (ANOVA P = 0.006) increased
significantly. Values are expressed in mean ± sd. °Values of 21 patients.
Pairwise comparisons *P < 0.05
T0 T30 T60 T90
RemiCe (ng ml-1)
Intubation 2.2 ± 0.3 2.3 ± 0.2 2.3 ± 0.2 2.3 ± 0.2
Incision 6.1 ± 2.6 5.8 ± 2.7 5.2 ± 2.1 4.6 ± 1.7
Extubation 2.2 ± 0.9 __ __ __
PropCe (µg ml-1)
Intubation 5 ± 1 4.9 ± 1 4.9 ± 1 4.9 ± 1
Incision 2.6 ± 0.9 2.6 ± 0.9 2.6 ± 0.9 2.6 ± 0.9
Extubation 1 ± 0.4 __ __ __
SBP (mmHg)
Intubation 112.8 ± 21.1 119.9 ± 22.2 123.2 ± 19.7* 122.1 ± 20*
Incision 103.6 ± 21.3 108.1 ± 26.2 111.7 ± 26.9 110.7 ± 25.3
Extubation° 137.3 ± 38.1 139 ± 34.2 140.9 ± 34.4 139.4 ± 30.4
HR (bpm)
Intubation 67.6 ± 13.8 75.7 ± 18.5 74.9 ± 17.9 72.8 ± 7.5
Incision 58.3 ± 10.8 57.8 ± 10.4 58.6 ± 10.7 58.8 ± 9.9
Extubation 73.6 ± 22.3 75.9 ± 19.5 78 ± 19.5 73.8 ± 22.5
BIS
Intubation 32.2 ± 7.5 34.4 ± 7.6 32.2 ± 7.7 31.4 ± 6.8
Incision 36.6 ± 7.3 37 ± 5.6 39.1 ± 7 40.2 ± 7.2
Extubation 88.6 ± 10.9 87.4 ± 10.6 88.6 ± 9.1 87.3 ± 10.1
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of time required to achieve equilibration between
plasma and effect concentrations of the drugs (20).
This period depends on the value of the pharmaco-
kinetic parameter ke0 which also influences the time
to peak compartment effect after bolus administra-
tion (18). For remifentanil, a period of approxi-
mately 2 minutes after a bolus is sufficient to allow
the equilibrium between plasma and effect concen-
trations (13). At skin incision, there were no signif-
icant changes in heart rate or blood pressure sug-
gesting that the remifentanil concentrations used
were adequate to prevent significant haemodynam-
ic responses to the noxious stimulus. We did no test
if lower remifentanil concentrations would allow us
to achieve the same results. However, the fact that
the blood pressure and heart rate did not drop as
response to the increasing remifentanil concentra-
tions also suggests that the remifentanil concentra-
tions were adequate when incision was performed.
At emergency from anaesthesia, anaesthetic
concentrations must be compatible with sponta-
neous ventilation while still providing good resid-
ual analgesia. Tolerance to analgesia during
remifentanil infusion is profound and develops very
rapidly (19). It is also known that intraoperative use
of remifentanil may result in increased postopera-
tive pain (9). Although the effects of remifentanil
dissipate rapidly after ending an IV infusion (5-
10 minutes), remifentanil provides more effective
postoperative analgesia than does intraoperative
treatment with morphine followed by morphine
boluses (21). Postoperative pain should be treated
according to the patient’s needs, eventually using
non-steroid drugs or longer acting opioids (1).
Predicted effect site concentrations are proba-
bly meaningless to the anaesthesiologists who have
never used TCI systems and are only accustomed to
infusion rates. This is particularly true with remifen-
tanil, since only recently commercial systems
became available. In order to help one understand
how remifentanil predicted concentrations (ng ml-1)
translate into infusion rates (µg kg-1 min-1) we have
calculated the infusion rates used in our patients at
several time periods (table II). The remifentanil
infusion rate used after extubation in our study was
0.05 ± 0.02 µg kg-1 min-1. This infusion rate is much
lower than what has been reported. BOWDLE and col-
leagues (3) used a remifentanil infusion rate from
0.05 µg kg-1 min-1 to 0.15 µg kg min-1 to provide
postoperative analgesia following abdominal, spine,
joint replacement or thoracic surgery. YARMUSH and
colleagues (21) suggested similar remifentanil infu-
sion rates for surgery procedures excluding cardiac,
neurosurgery and peripheral vascular surgery, with
a reported maximum infusion rate of 0.23 µg kg-1
min-1. The lower doses used in our study could be
due to the administration of paracetamol and pare-
coxib one hour before the end of surgery or to a dif-
ference in post-operative analgesia requirements for
neurosurgical procedures.
Fig. 1. — Heart rate (HR) (bpm), systolic blood pressure (SBP) (mmHg) and BIS values of each individual patient at intubation, inci-
sion and extubation (0 seconds) and 30, 60 and 90 seconds after. At intubation it was observed a statistically significant increase in
systolic blood pressure (P = 0.003) and heart rate (P = 0.006).
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In conclusion, the remifentanil predicted con-
centrations used during the different phases of the
procedures proved to be clinically adequate to min-
imize the haemodynamic response to stimulation.
The remifentanil concentrations used in our patients
tend to be lower than reported or recommended
concentrations which, with the exception of intuba-
tion, may be due to the fact that the patients in our
study were neurosurgical patients. We believe that
demonstrating that remifentanil concentrations
around 2.2 ng ml-1 for intubation, 6.1 ng ml-1 for
incision and 2.2 ng ml-1 for extubation may be of
clinical use for anaesthesiologists who are starting
to use TCI systems in neurosurgical patients. Our
results also showed that it was safe to extubate
patients with remifentanil predicted cerebral con-
centrations around 2 ng ml-1 while maintaining
blood pressure near awake values and a propofol
predicted effect site concentration of 1 µg ml-1. It is
worth to note that there is no such thing as an “opti-
mum recipe” for adequate anaesthesia, nor this
work tries to do so. There are a large number of pos-
sible combinations of target levels that will also
produce good anaesthesia. Only experience will
allow the achievement of a smooth anaesthesia.
Other departments and countries certainly have
slightly different approaches, all of which are valid.
TCI with propofol and remifentanil is a safe anaes-
thetic technique for neurosurgical procedures. It
allows an easy control of patients’ haemodynamic
and electroencephalographic variables, and a
smooth awakening.
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